Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1997 Apr;25(2):149-67.
doi: 10.1023/a:1025728028890.

Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling

V F Cosson  1 , E Fuseau, C Efthymiopoulos, A Bye
Affiliations

Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling

V F Cosson et al. J Pharmacokinet Biopharm. 1997 Apr.

Abstract

Allometric scaling is an empirical examination of the relationships between the pharmacokinetic parameters and size (usually body weight), but it can also involve brain weight for metabolized drug. Through all species, the protein binding of sumatriptan is similar (14-16%), and its metabolic pathway undergoes extensive oxidative deamination involving the monoamine oxidase A isoenzyme. These similarities across species suggested the possible relevance of an allometric analysis. Toxicokinetic data were collected from rats, pregnant rabbits, and dogs in animal pharmacokinetic studies where sumatriptan was administered intravenously to the animals at doses of 5 mg/kg. 0.25 mg/kg, and 1 mg/kg, respectively. Animal data were pooled and analyzed in one step using a mixed effect modeling (population) approach. The kinetic parameters predicted in any species were close to the observed values by species: 77 L/hr vs. 80 L/hr in man for total clearance, 137 L vs. 119 L for distribution volume at steady state. The value of the mixed effect modeling approach compared to the two-step method was demonstrated especially with the possibility of including covariates to describe the status of animal (e.g., pregnancy) in the model. Knowledge of the animal kinetics, dynamics, and metabolism of a drug contributes to optimal and expeditious development. Valuable information for the design of the first-dose-in-man study may emerge from more creative data analysis based on all the information collected during the preclinical and ongoing nonclinical evaluation of a new drug.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Eur Neurol. 1991;31(5):282-90 - PubMed
    1. J Pharm Sci. 1985 Oct;74(10):1097-9 - PubMed
    1. Pharm Res. 1995 Jun;12(6):895-901 - PubMed
    1. Drug Metab Dispos. 1993 Sep-Oct;21(5):761-9 - PubMed
    1. Drug Metab Rev. 1984;15(5-6):1071-121 - PubMed

LinkOut - more resources